Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTA NASDAQ:KURA NASDAQ:TYRA NASDAQ:UPB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$7.75+1.3%$6.58$4.09▼$17.24$165.70M0.84282,258 shs114,671 shsKURAKura Oncology$5.81+2.3%$6.10$5.41▼$23.48$502.97M0.41.25 million shs953,109 shsTYRATyra Biosciences$9.91+3.1%$9.85$6.42▼$29.60$526.12M1.07287,174 shs311,398 shsUPBUpstream Bio$10.90-0.7%$10.04$5.14▼$29.46$586.36MN/A351,824 shs207,281 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals-3.04%+1.19%+2.41%+71.52%-42.87%KURAKura Oncology-3.89%-1.56%-15.60%+1.07%-71.61%TYRATyra Biosciences-3.85%+0.42%-8.91%+36.12%-43.80%UPBUpstream Bio-1.96%0.00%-2.57%+80.89%+1,097,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.6322 of 5 stars3.42.00.04.70.02.50.0KURAKura Oncology4.5441 of 5 stars4.43.00.04.71.90.80.6TYRATyra Biosciences1.8178 of 5 stars3.50.00.00.01.73.30.0UPBUpstream Bio1.3772 of 5 stars3.50.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$18.00132.26% UpsideKURAKura Oncology 2.86Moderate Buy$24.50321.69% UpsideTYRATyra Biosciences 3.00Buy$30.83211.13% UpsideUPBUpstream Bio 3.00Buy$56.50418.35% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, TYRA, UPB, and KURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.006/3/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.005/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/2/2025KURAKura OncologyBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $11.004/29/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.00 ➝ $28.004/28/2025KURAKura OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.004/8/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$36.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$67.64M2.45N/AN/A$6.08 per share1.27KURAKura Oncology$53.88M9.34N/AN/A$5.32 per share1.09TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/AUPBUpstream Bio$2.30M255.38N/AN/A$8.77 per share1.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)KURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%8/6/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)UPBUpstream Bio-$62.81MN/A0.00N/AN/AN/AN/AN/A8/5/2025 (Estimated)Latest ENTA, TYRA, UPB, and KURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025UPBUpstream Bio-$0.61N/AN/AN/A$0.32 millionN/A8/4/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.10N/AN/AN/A$16.21 millionN/A5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025UPBUpstream Bio-$0.49-$0.51-$0.02-$0.51$0.71 million$0.57 million5/1/2025Q1 2025KURAKura Oncology-$0.51-$0.66-$0.15-$0.66$39.08 million$14.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/AUPBUpstream BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.295.29KURAKura Oncology0.028.078.07TYRATyra BiosciencesN/A22.7822.78UPBUpstream BioN/A47.4347.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%KURAKura OncologyN/ATYRATyra Biosciences84.14%UPBUpstream BioN/AInsider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%KURAKura Oncology6.40%TYRATyra Biosciences15.20%UPBUpstream Bio13.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableTYRATyra Biosciences2053.09 million45.02 millionOptionableUPBUpstream Bio3853.79 million46.50 millionN/AENTA, TYRA, UPB, and KURA HeadlinesRecent News About These CompaniesUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...July 8 at 9:23 AM | bakersfield.comBUpstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory PortfolioJuly 8 at 7:52 AM | quiverquant.comQUpstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)July 8 at 7:00 AM | globenewswire.comUPB Upstream Bio, Inc. - Seeking AlphaJune 28, 2025 | seekingalpha.comUpstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?June 20, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?June 18, 2025 | marketbeat.comUpstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What HappenedJune 16, 2025 | marketbeat.comUpstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody SpaceJune 16, 2025 | tipranks.comUpstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher PotencyJune 15, 2025 | msn.comUpstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI CongressJune 15, 2025 | quiverquant.comQTranslational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP ReceptorJune 15, 2025 | globenewswire.comUpstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025June 5, 2025 | quiverquant.comQUpstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025June 5, 2025 | globenewswire.comUpstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comUpstream Bio names new chief technology officerMay 21, 2025 | investing.comUpstream Bio Appoints Stacy Price As CTOMay 21, 2025 | nasdaq.comUpstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical OperationsMay 21, 2025 | nasdaq.comUpstream Bio Appoints Stacy Price as Chief Technology OfficerMay 20, 2025 | globenewswire.comUpstream Bio Advances Verekitug in Clinical TrialsMay 7, 2025 | tipranks.comUpstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial PositionMay 6, 2025 | tipranks.comUpstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical ProgramsMay 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not Hype3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedBy Jeffrey Neal Johnson | June 18, 2025View 3 Catalysts in 7 Days: Archer's Growth Story Just AcceleratedSuper Micro Computer Stock's Rally Backed by Strong FinancialsBy Gabriel Osorio-Mazilli | June 19, 2025View Super Micro Computer Stock's Rally Backed by Strong FinancialsRetail Sales Signal Upside for These 3 Consumer StocksBy Gabriel Osorio-Mazilli | June 22, 2025View Retail Sales Signal Upside for These 3 Consumer StocksSnag These 3 Bargain Tech Stocks Before They PopBy Gabriel Osorio-Mazilli | June 27, 2025View Snag These 3 Bargain Tech Stocks Before They PopENTA, TYRA, UPB, and KURA Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$7.75 +0.10 (+1.31%) As of 04:00 PM EasternEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Kura Oncology NASDAQ:KURA$5.81 +0.13 (+2.29%) Closing price 04:00 PM EasternExtended Trading$5.98 +0.18 (+3.01%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Tyra Biosciences NASDAQ:TYRA$9.91 +0.30 (+3.12%) As of 04:00 PM EasternTyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Upstream Bio NASDAQ:UPB$10.90 -0.08 (-0.73%) As of 04:00 PM EasternUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
